Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019062250) THERAPEUTIC AGENT COMPRISING ISOLATED RECOMBINANT ONCOLYTIC ADENOVIRUS AND NK CELL, APPLICATION, KIT, AND METHOD FOR TREATMENT OF TUMOR AND/OR CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/062250 International Application No.: PCT/CN2018/094263
Publication Date: 04.04.2019 International Filing Date: 03.07.2018
IPC:
A61P 35/00 (2006.01) ,C12N 15/861 (2006.01) ,C12N 7/01 (2006.01) ,A61K 38/19 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
86
Viral vectors
861
Adenoviral vectors
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01
Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
Applicants:
杭州康万达医药科技有限公司 HANGZHOU CONVERD CO., LTD. [CN/CN]; 中国浙江省杭州市 余杭区仓前街道余杭塘路2959号4幢7层 7th Floor, Building #4, 2959 Yuhangtang Road, Yuhang District Hangzhou, Zhejiang 311121, CN
Inventors:
绳纪坡 SHENG, Jipo; CN
傅瑾 FU, Jin; CN
赵荣华 ZHAO, Ronghua; CN
秦云 QIN, Yun; CN
陈霖 CHEN, Lin; CN
康三毛 KANG, Sanmao; CN
胡放 HU, Fang; CN
Agent:
北京天昊联合知识产权代理有限公司 TEE & HOWE INTELLECTUAL PROPERTY ATTORNEYS; 中国北京市 东城区建国门内大街28号民生金融中心D座10层樊晓焕 FAN, Xiaohuan 10th Floor, Tower D, Minsheng Financial Center, 28 Jianguomennei Avenue, Dongcheng District Beijing 100005, CN
Priority Data:
201710899291.628.09.2017CN
Title (EN) THERAPEUTIC AGENT COMPRISING ISOLATED RECOMBINANT ONCOLYTIC ADENOVIRUS AND NK CELL, APPLICATION, KIT, AND METHOD FOR TREATMENT OF TUMOR AND/OR CANCER
(FR) AGENT THÉRAPEUTIQUE COMPRENANT UN ADÉNOVIRUS ONCOLYTIQUE RECOMBINANT ISOLÉ ET UNE CELLULE NK, APPLICATION, KIT, ET MÉTHODE DE TRAITEMENT D'UNE TUMEUR ET/OU D'UN CANCER
(ZH) 包含分离的重组溶瘤腺病毒和NK细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
Abstract:
(EN) A therapeutic agent comprising an isolated recombinant oncolytic adenovirus and an NK cell, an application, a kit, and a method for treatment of a tumor and/or cancer. The therapeutic agent comprises: a first pharmaceutical composition, the first pharmaceutical composition comprising a recombinant oncolytic adenovirus in a first pharmaceutically-acceptable carrier; and a second pharmaceutical composition, the second pharmaceutical composition comprising an NK cell in a second pharmaceutically-acceptable carrier. The recombinant oncolytic adenovirus is a replication-selective oncolytic adenovirus, and a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells is integrated in a genome of the recombinant oncolytic adenovirus. The oncolytic killing effect of the recombinant oncolytic adenovirus and the anti-tumor immunostimulatory effect of a T lymphocyte produce a synergistic effect. Using the recombinant oncolytic adenovirus and the NK cell in combination can produce a further synergistic tumor-killing effect.
(FR) L'invention concerne un agent thérapeutique comprenant un adénovirus oncolytique recombinant isolé et une cellule NK, une application, un kit et une méthode de traitement d'une tumeur et/ou d'un cancer. L'agent thérapeutique comprend : une première composition pharmaceutique, la première composition pharmaceutique comprenant un adénovirus oncolytique recombinant dans un premier véhicule pharmaceutiquement acceptable ; et une seconde composition pharmaceutique, la seconde composition pharmaceutique comprenant une cellule NK dans un second véhicule pharmaceutiquement acceptable. L'adénovirus oncolytique recombinant est un adénovirus oncolytique à réplication sélective, et une séquence codante d'ARNsh exogène pouvant inhiber l'expression de PDL1 dans des cellules tumorales est intégrée dans un génome de l'adénovirus oncolytique recombinant. L'effet destructeur oncolytique de l'adénovirus oncolytique recombinant et l'effet immunostimulant anti-tumoral d'un lymphocyte T produisent un effet synergique. L'utilisation de l'adénovirus oncolytique recombinant et de la cellule NK en association peut produire un effet synergique de destruction tumorale supplémentaire.
(ZH) 一种包含分离的重组溶瘤腺病毒和NK细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法。治疗剂包含第一药物组合物,其中该第一药物组合物包含位于第一可药用载体中的重组溶瘤腺病毒;和第二药物组合物,其中该第二药物组合物包含位于第二可药用载体中的NK细胞。重组溶瘤腺病毒为选择复制型溶瘤腺病毒,并且该重组溶瘤腺病毒的基因组中整合有能够在肿瘤细胞中抑制PDL1表达的外源shRNA的编码序列。重组溶瘤腺病毒使其溶瘤杀伤作用和T淋巴细胞的抗肿瘤免疫刺激作用产生协同效果。重组溶瘤腺病毒与NK细胞联用可产生进一步协同杀伤肿瘤的作用。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)